**Author details**

Mümtaz Güran Faculty of Medicine, Eastern Mediterranean University, Famagusta, Turkey

\*Address all correspondence to: mumtaz.guran@emu.edu.tr

© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**83**

*An Overview of Leishmaniasis: Historic to Future Perspectives*

transmission. Memórias do Instituto Oswaldo Cruz. 2000;**95**(4):589-590

emergence in Europe. Eurosurveillance.

[12] Ribeiro PAF et al. Evaluation of a Leishmania hypothetical protein administered as DNA vaccine or recombinant protein against Leishmaniainfantum infection and its immunogenicity in humans. Cellular

[13] Leishman WB. On the possibility of the occurrence of trypanosomiasis in India. British Medical Journal.

[14] Gotoff SP, Esterly NB. Histiocytosis. The Journal of Pediatrics. 1 Oct 1974;

[16] Gökmen TG, Haytoglu S, Güran M, Kusçu F, Köksal F. A multidisciplinary approach to an uncommon case of laryngeal leishmaniasis in Turkey. Journal of Vector Borne Diseases.

[17] Barroso DH, Silva CEF, e Vasconcelos ACDP, Cavalcanti SM d M, de Brito MEF, Medeiros ACR. Post-kala-azar dermal leishmaniasis in two different clinical contexts. Anais Brasileiros de Dermatologia. 2015;**90**(3):108-110

[18] Von Stebut E. Leishmaniasis. Journal der Deutschen Dermatologischen Gesellschaft. 2015;**13**(3):191-201

[19] Salam N, Al-Shaqha WM, Azzi A. Leishmaniasis in the middle East: Incidence and epidemiology. *PLoS Neglected Tropical Diseases*. 2014;**8**(10):1-8

[20] Rioux J, Jalouk L, Khiami A, Ilaboratoire CD. Evidence for a

[11] Ready PD. Leishmaniasis

Immunology. 2018;**331**:67-77

1903;**2**(2238):1376-1377

[15] Ross MR. Further notes on leishman's bodies. British Medical Journal. 1903;**2**(2239):1401

**85**(4):592-594

2014;**51**(2):140-143

2010;**15**(10):29-39

*DOI: http://dx.doi.org/10.5772/intechopen.81643*

[1] Akbari M, Oryan A, Hatam G. Application of nanotechnology in treatment of leishmaniasis: A review.

[2] Handler MZ, Patel PA, Kapila R, Al-Qubati Y, Schwartz RA. Cutaneous and mucocutaneous leishmaniasis: Clinical perspectives. Journal of the American Academy of Dermatology.

[3] Pace D. Leishmaniasis. The Journal of

Infection. 2014;**69**(S1):S10-S18

[4] Di Muccio T et al. Epidemiology of imported leishmaniasis in Italy: Implications for a European endemic country. PLoS ONE. 2015;**10**(6):1-16

[5] Antinori S, Gianelli E, Calattini S, Longhi E, Gramiccia M, Corbellino M. Cutaneous leishmaniasis: An increasing threat for travellers. Clinical Microbiology and Infection.

[6] Oryan A, Akbari M. Worldwide risk factors in leishmaniasis. Asian Pacific Journal of Tropical Medicine.

[7] Alvar J et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE. 2012;**7**(5):e35671

[9] Bates PA. Transmission of

by phlebotomine sand flies.

2007;**37**(10):1097-1106

Leishmaniametacyclicpromastigotes

International Journal for Parasitology.

[10] Ready PD. Sand fly evolution and its relationship to Leishmania

[8] Mohammadi MA, Bamorovat M, FasihiHarandi M, Karimi T, Sharifi I, Aflatoonian MR. Comparison of three PCR-based methods for simplicity and cost effectiveness identification of cutaneous leishmaniasis due to Leishmaniatropica. Iranian Journal of Parasitology. 2017;**12**(2):215-223

Acta Tropica. 2017;**172**:86-90

2015;**73**(6):897-908

2005;**11**(5):343-346

2016;**9**(10):925-932

**References**

*An Overview of Leishmaniasis: Historic to Future Perspectives DOI: http://dx.doi.org/10.5772/intechopen.81643*
